BioPharma

Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease. Source: BioSpace

The second time proved to be the charm for the U.S. House of Representatives to pass right-to-try legislation that would provide terminally ill patients access to experimental drugs without the approval of the U.S. FDA. Source: BioSpace

Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business. Source: BioSpace

Array BioPharma Inc. released detailed results for its late-stage combination treatment for metastatic melanoma. Source: BioSpace

Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis. Source: BioSpace

Seattle Genetics announced today that the FDA has granted approval for its Adcetris drug to treat Hodgkins Lymphoma. Source: BioSpace

Billions of dollars are being invested in Boston-based life science companies. Source: BioSpace

TCR2 Therapeutics has raised $125 million in Series B financing to advance two T-Cell receptor (TCR) programs through clinical proof-of-concept. Source: BioSpace

Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down. Source: BioSpace

Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases. Source: BioSpace